Momelotinib: First Approval
- PMID: 37989928
- DOI: 10.1007/s40265-023-01964-8
Momelotinib: First Approval
Abstract
Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that has been developed for the treatment of myelofibrosis (MF). In September 2023, momelotinib was approved in the USA for the treatment of intermediate or high-risk MF, including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. This article summarizes the milestones in the development of momelotinib leading to this first approval for MF.
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.Future Oncol. 2017 Feb;13(5):395-407. doi: 10.2217/fon-2016-0417. Epub 2016 Oct 27. Future Oncol. 2017. PMID: 27785927 Review.
-
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.Leuk Res. 2017 Sep;60:11-17. doi: 10.1016/j.leukres.2017.05.002. Epub 2017 May 30. Leuk Res. 2017. PMID: 28622623 Free PMC article. Clinical Trial.
-
Momelotinib for the treatment of myelofibrosis with anemia.Future Oncol. 2022 Jun;18(20):2559-2571. doi: 10.2217/fon-2022-0276. Epub 2022 May 23. Future Oncol. 2022. PMID: 35603634 Review.
-
Momelotinib: an emerging treatment for myelofibrosis patients with anemia.J Hematol Oncol. 2022 Jan 19;15(1):7. doi: 10.1186/s13045-021-01157-4. J Hematol Oncol. 2022. PMID: 35045875 Free PMC article. Review.
-
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.Future Oncol. 2021 Apr;17(12):1449-1458. doi: 10.2217/fon-2020-1048. Epub 2021 Jan 11. Future Oncol. 2021. PMID: 33423550
Cited by
-
New and emerging oral therapies for psoriasis.Drugs Context. 2024 Aug 1;13:2024-5-6. doi: 10.7573/dic.2024-5-6. eCollection 2024. Drugs Context. 2024. PMID: 39131603 Free PMC article. Review.
-
Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study.Ann Hematol. 2024 Sep;103(9):3605-3613. doi: 10.1007/s00277-024-05847-0. Epub 2024 Jun 22. Ann Hematol. 2024. PMID: 38907072
References
-
- GlaxoSmithKline. OJJAARA (momelotinib): US prescribing information 2023. https://ojjaara.com/ . Accessed 19 Sep 2023.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous